key: cord-0948402-l90sle3z authors: Saeed, Balsam Qubais; Al-Shahrabi, Rula; Alhaj, Shaikha Salah; Alkokhardi, Zainab Mansour; Adrees, Ahmed Omar title: Side Effects and Perceptions Following Sinopharm COVID-19 Vaccination date: 2021-08-09 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.08.013 sha: 121e384a4995dcc1dd1b47f610bff77ccb06583c doc_id: 948402 cord_uid: l90sle3z OBJECTIVES: : Vaccines are one of the best interventions developed for eradicating COVID-19,. The aim of this study to provide evidence on Sinopharm COVID-19 vaccine side effects. METHODS: : A cross-sectional survey study was conducted between January and April 2021 to collect data on the effects of COVID-19 vaccine among individuals in the UAE. Demographic data. vaccination, and the response of people not willing to take COVID-19 vaccine were reported. RESULTS: : The most common side effects of post 1(st) dose (≤49 years old vs >49 years) were normal injection site pain, fatigue, and headache, while pain at the vaccination site, fatigue, lethargy, headache, and tenderness were the most side effects of the post 2(nd) dose in both groups. All the side effects in both doses were more prevalent among the participants ≤ 49-year-old group. Among female's vs males, side effects were more common in females compared with males in both doses. . The most common reason of not willing to take the COVID-19 vaccine were the vaccines are not effective. CONCLUSION: : The 1st and 2nd dose post-vaccination side effects were mild, predictable, and there were no hospitalization cases, this data will help to reduce the vaccine hesitancy. studies only focus on Sinopharm COVID-19vaccine [16, 17] , moreover, fear of the new vaccine is a driver of vaccine hesitancy [18] . The knowledge about what happens post vaccination in the actual world among the general population is still modest, Thus, by describing what to expect after 1 st and 2 nd dose of vaccination will help in lowering the apprehension about this type of vaccines, increase the public confidence in the vaccines, safety, and accelerate the vaccination process against COVID-19. [16, 17] . The results of this study will be reassuring to those who are fearful of the Sinopharm COVID-19 vaccine. So, the goal of this study was to provide evidence on Sinopharm COVID-19 vaccine side effects after receiving 1 st and 2 nd dose of it, which is approved by UAE. This cross-sectional survey-based study was carried out from 10 th January 2021 to 30 th April 2021, to evaluate the Sinopharm COVID-19 vaccine adverse reactions among residents in the UAE. The study utilized a self-administered online survey created on Google Forms which had been randomly delivered to individuals (18 years and older) using social media sites (Facebook, Email, and WhatsApp). Potential participants were directed to a page that included brief introduction to the aim and purpose of the study in addition to instructions on how to complete the survey. Informed consent form that included statements about voluntary participation and anonymity was sought from all the respondents prior to data collection by sending a standardized general invitation letter with the survey link to accept or decline to participate in the study. The participant who declined consent were not permitted to open the survey and participate in the study, and participants could withdraw from the survey at any time in line with stipulations of the World Medical Association Declaration of Helsinki Ethical principles [19] . The members who clicked on the link were directed to the Google forms and to avoid the missing data, the participants were requested to fill all the questions of the survey or else could not proceed to the next section. No incentives or compensations have been given to participants [20] . The total number of respondents was calculated. Out of 1102 survey received from respondents, 1080 participants were included in this study aged 18 years and above from different emirates and nationalities. The study sample included the participants who are either vaccinated with the first dose or the second dose of Sinopharm COVID-19 vaccine , moreover, the participants who didn't get any COVID-19 vaccine during the early peak of the vaccination campaign in UAE were included in this study. Individuals under 18 years old and the visiting people who are not residents in the UAE were excluded from this study as they were not allowed to take any vaccine type in the UAE during the conduct of this study. In addition, individuals who had received another type of COVID-19 vaccine were not included in the study based on the aim of this study. The Survey was designed based on previous extensive literature search studies, and guidelines of WHO, MOHAP, DOH in UAE on the expected Adverse reactions post Sinopharm COVID-19 vaccine. the questions of survey were multiple choice, the survey was created in English and Arabic languages. [8, 15, 21] , it was validated by a group of experts who provided feedback on the different items of the survey. The survey were included three sections, the first section included 7 demographic questions such as (gender, age, marital status, education level, employment, nationality, and, the region of living) second section reviewed participant's chronic conditions such as : cancer, autoimmune diseases, chronic respiratory diseases, diabetes, hypertension, obesity, heart disease, allergic reactions to vaccination (any type of immediate allergic reaction to a vaccine or injectable therapy), receiving immunotherapy or inhibitor therapy, severe anemia (level less than 7.0 g/dl), liver diseases, and no chronic condition. The last section was related to Sinopharm COVID-19 vaccine side effects. In the first section participant has been asked about his/her COVID-19 vaccination status to determine the scope of the rest of the questions, however, if the participant received the vaccine, we asked them about number of doses administered and the previous infection to COVID-19, then questions regarding vaccine 1 st and 2 nd dose side effects were asked separately based on each dose side effects, mentioning : (normal/severe pain at the vaccination site, tenderness, redness, pruritus at the vaccination site, fever, headache, fatigue, nausea, diarrhea, cough, allergy, muscle pain, abdominal pain, back pain, lethargy) . If the participant did not receive any COVID-19 vaccine, a question to clarify the reasons behind the participant's hesitancy takes place. For pilot testing, a questionnaire was passed randomly to 15 participants recently vaccinated and filled the questionnaire after taking the two doses and have been excluded from the study.. The Cronbach's alpha test of internal consistency was used to evaluate survey reliability. The overall reliability was equal to 0.81, which indicates that the survey tool was reliable with good internal consistency [22, 23] . The online Raosoft sample size calculator (Raosoft Inc., Seattle, WA, USA) was used to calculate the sample size of our study. Based on world meter elaboration of the latest United Nations data the UAE population is approximately 10 million, around 77.3% of total population received at least one dose of the vaccine (according to UAE supreme council for national security), we assumed the confidence level is 95%, margin error is 3%, response distribution 50% with population number 7.7 million (vaccinated with at least one dose), sample size recommended was 1067, and the respondents in this study were 1080, which means convenience sample size was used In our study the mean age was 37.2±13.1, given the fact that age has been classified into four groups ranged from the minimum of 18 to the maximum of 80 years old, median age of our 49 years old selected to be a cutting point to evaluate the differences of participant's sample side effects between two groups (≤49 vs ) using a Chi-squared test. Similarly, Chi->49 squared test was performed to assess the correlation between the presence of vaccine side effects and gender tolerability. Demographic characteristics conditions. The most prevalent chronic conditions as shown in table 2 were diabetes 7.8% followed by hypertension 6.3%, while 3.7%, 3.7%, 3.3%,0.7%, 0.7%, 0.4%, 0.4%, 0.4%, 0.4% suffer of chronic respiratory diseases, heart diseases, obesity, cancer, severe anemia, autoimmune diseases, severe allergic, receiving immunotherapy, and liver diseases, respectively. Relation between the side effects of vaccination with the age (≤49 years old and >49 years old) Table 3 compares COVID-19-related anamnesis of vaccinated individuals who are below and above the age 49. Regarding whom is vaccinated, the study shows a significant difference between people who are ≤49 years old and >49 years old (p=0.000). Participants who are older than 49 years were more likely to be vaccinated (85%) compared to the ones below 49 years (75%). The results regarding number of doses were not significant (p=0.128). There was a significant difference in whether the participants got Covid-19 infection previously or not with a P value of 0.002. Those who are less or equal to 49 years were more likely to have a previous COVID-19 infection (16.6%). Table 4 . presents the prevalence of general adverse reaction of 1 st dose of Sinopharm COVID-19 vaccine in participants (≤49 years old vs >49 years old). The table shows that the around 24.4% (26% vs 18.6%) didn't get any side effects. The common side effects among both ages of participants were normal pain at the site of vaccination 42.2%, fatigue 12.2%, and headache 9.6%), the same table indicated that was a significant difference between both groups (≤49 years vs >49 years old) with the severe pain at the vaccination site (P= 0.023), nausea (P=0.010) and muscle pain (P=0.010). Moreover, almost 6.8% of participants >49 years reported sever pain at the vaccination site while, compared with 1.42% among ≤49 years old. More proportion of participants who are >49 years old reported nausea and muscle pain compared to patients ≤49 years, it was (0.5% vs 5%) and (4.3% vs 13.6%), respectively. The tables shows that no significant between age of participant and another side effects such In the 2 nd dose of Sinopharm COVID-19 vaccine (≤49 years vs >49 years old) there were more prevalence of side effects than the 1 st dose (table 5) . Among the (≤49 years vs >49 years old) participants, 14% (15% vs 10%) didn't get any post-vaccination symptoms. Furthermore, pain 32.6%, at the vaccination site, fatigue16.3%, lethargy13.7%, headache10%, and tenderness 10% are the most prevalence side effects of the respondents in both groups. The same table shows there was a significant difference between both groups (≤49 years vs >49 years old) and the fatigue (P= 0.003), while no significant difference reported with other side effects. Relation between the side effects of vaccination with the gender (females and males) Table 6 shows the prevalence of side effects post 1 st dose of Sinopharm COVID-19 vaccination among two groups (females vs males). Our study was included 760 females and 320 males. The female's significance had more symptoms of 1 st vaccination than males (17% of females didn't have side effects vs 45% males didn't have side effects), however, significant relation reported between the symptoms such as fatigue (P=0.006) and gender. The results shows that no significant between the side effects of tenderness (P= 0.194), redness (p-value= 0.356), fever (P= 0.891) and headache (p-value= 0.434) with the gender. Table 7 presents the prevalence of side effects of 2nd dose of vaccination among females and males. The females had more side effect of 2 nd vaccination dose than males (11.6% of females didn't have side effects vs 20% males didn't have side effects), Sever pain at the vaccination site (P=0.027) and fatigue (P = 0.011) symptoms were significantly higher in females than males (10.5% vs 2.5%), (20% vs 7.5%), respectively. In addition, the table shows no significant between the symptoms of normal pain at vaccination site (P=0.482), tenderness (P= 0.368), redness (P = 0.834) fever (P = 0.279), and lethargy (P =0.053) with the genders. The most three common reasons reported by participants for not willing to take the vaccine were 6.3% not believing that the vaccine is effective, 5.2% pant wasn't authorized to take the vaccine and, 4.4% of them belief that the vaccine have many side effects, Moreover, the participants reported that -not have enough time‖ 3.7%, unavailability of the vaccine 3%, the vaccines is not approved by WHO‖ 1.5%, being afraid of needles 1.1% and the least common reason was -waiting for another vaccine‖ 0.4% (table 8) . In August 2020, Trial 1 and 2 of Sinopharm vaccine were completed and showed that the vaccine triggered a COVID-19 neutralizing antibody response with a low rate of adverse reactions. The most common adverse reactions were pain at the site of injection and fever, but all these were mild and self-limiting, moreover, no treatment was required for any side effect [8] . UAE were among the first to conduct phase three clinical trials of the vaccine, they found the vaccine to have an 86% efficacy rate according to interim results of its phase 3 trial [8] . Most of studies have assessed mainly the post-vaccination adverse reactions of the Pfizer-BioNTech, Moderna, and Astrazeneca vaccines [26, 27, 28, 29, 30] , while only two studies focus on Sinopharm COVID-19 vaccine [16, 17] , There are no published studies yet that have focused on Sinopharm COVID-19 vaccine side effects in UAE. The finding of our study shows that the side effects of this vaccines appear to be mild. Anecdotally, a quarter of participants reported they didn't get any symptom in postfirst vaccination shot, while had mild symptoms following vaccination. In second dose 14% didn't report any symptoms, however, most of them had mild and predictable side effects. None of the side effects were a serious nature or required hospitalization. Our results were in line of a study in India, as frequency of experiencing symptoms following each vaccine were 24.4% (Sinopharm). [16] . In first dose of vaccination the findings showed a statistically significant differences in the prevalence of severe pain at the vaccination site, nausea, and muscle pain, between the participants in both groups (≤49 vs >49). While in the 2 nd dose showed a significant difference in the prevalence of fatigue between two groups. Moreover, more frequent side effect prevalence is normal pain at the vaccination site (42.2%), fatigue (12.2%) headache (9.6%), lethargy (9.2%), and muscle pain (6.3%). The reported symptoms in our study were similar to symptoms that appear on participants in phase 1/2 trial of Sinopharm vaccine and reported by Sinopharm vaccine company, WHO, DOH and MOH in the UAE reported that the most adverse reactions were injection site reactions, headaches, fatigue, they indicated that the most common systematic adverse reaction was pain at the vaccination site fever, it was self-limited and recovered, none of the symptoms were of serious nature or requiring hospitalization. [8, 15, 21] . Injection site pain symptom reported in several literatures on vaccines' side effects [16, 17, 29, 30] , injection in a relaxed muscle leads to less pain compared to a tensed one; therefore, the researchers recommended to lower the patient's arm that will be injected to reduce the pain. In addition, vaccines in in situ should be keep it in a low temperature, including Sinopharm COVID-19 vaccine that should store at normal refrigeration temperature, and if injected without optimal warming up, this may increase the probability of pain of the injection site symptom. [ 17, 29, 31] . Comparing with other inactivated virus vaccines like CoronaVac, the evaluation report of the Food and Health Bureau (FHB) of Hong Kong SAR on CoronaVac reported that the very common adverse reactions (≥10%) were injection site pain, headache, and fatigue [32] . The study of Riad and others Riad and others among healthcare workers in Turkey found that the injection site pain (41.5%), fatigue (23.6%), and headache (18.7%) were reported by more than 10% of the participants, this result was similar to our result for Sinopharm COVID-19 vaccine [33] . In our study the younger adults (≤49) were more frequently affected than other groups (>49). Vaccine reactogenicity is known to correlate with transient elevation of inflammatory cytokines, suggesting that the vaccine reactogenicity declined with age, but it is not considered a reliable sign of a desirable immune response [34] . Similar to our results showed in various studies on COVID-19 vaccine side effects [16, 29, 35] , Moreover, according to the Centers for Disease Control and Prevention (CDC), the side effects tend to be more noticeable after the first dose [36] . Similar to the findings of recently published studies [17, 30] , we observed that the frequency of adverse effective in the second shot of vaccine was slightly higher than to the first dose except some symptoms (1 st vs 2 nd ), nausea (1.5% vs 1.1%), allergy (1.1% vs 0), cough (1.1% vs 0.7%), abdominal pain (1.85% vs 1.5%, back pain (4.07% vs 3%), this finding could be interpreted on the basis response of the immune system's. The immune system could produce cytokines that could have an inflammatory effect on the blood vessels, muscles, and other tissues, it may also produce flu-like symptoms that last for days after vaccination [7] . Women generally were more likely to have side effects of vaccination than males, as 83% of the females reported that had side effects compared to 55% reported by males' participants post 1 st dose of vaccination, while was (98.5% female vs, 80% males) for post 2 nd dose of vaccination. Previous studies on COVID-19 vaccine have reported more side effects within females compared to males in both doses [16, 29, 30] . According to the findings of the study on CoronaVac side effects, the local side effects and systemic side effects were more prevalent after the second dose in females than males, this demonstrates the similar efficacy of these vaccines [33] . The differences of side effects between genders in inactivated virus vaccines such as: influenza, measles-mumps-rubella combination vaccine (MMR), attenuated Japanese encephalitis, and attenuated Dengue vaccines reported that the females have stronger immune responses and the side effects were more frequent and more intense [37, 38] Allergic reactions to vaccines not attributed to the active vaccine itself, they might be caused by inactive ingredients, such as egg protein, gelatin, formaldehyde, thimerosal, or neomycin, that contribute to specific IgE-mediated immediate reactions. According to European Medicines Agency (EMA), Excipients, are constituents of a medicinal form apart from the active substance, it constitutes inert substances that are added to vaccines to improve stability, increase solubility, improve absorption, influence palatability, or create a distinctive appearance. Excipients can cause various clinical allergic reactions ranging from skin disorders to life-threatening systemic reactions [40] . In our study, we noticed that the most prevalent chronic conditions among the UAE participants were diabetes 7.80%, and hypertension 6.30%. Our results are consistent with the Dubai Statistical Center study that shows UAE nationals have a higher prevalence rate of diabetes and hypertension diseases, furthermore, another study among patients with chronic disease in the UAE reported that 74.1% of individuals were diabetics [41, 42] . Recent studies have shown that COVID-19 vaccine hesitancy level among residents varies from low to high. In New York about 29% of residents claimed that they will refuse a vaccine, compared to 20% of Canadians residents, and 6% of among them in the United Kingdom. [43, 44] . In our study, a few respondents reported that don't want to receive the COVID-19 vaccine, the common reasons of indecision and rejection about COVID-19 were belief that the vaccine not effective, some of the participants were from the categories who are not authorized to take vaccine, while 4.4% were afraid of side effects of the vaccine. Several studies in the scientific literature reported the similar reasons, Thus, knowing what to expect postvaccination from this study will help in public education, dispelling myths, and lowering the apprehension about Sinopharm COVID-19 vaccine. Similar reasons reported in several studies. In the study among individuals above 18 years of age the most common reasons for rejection of vaccine were that the participants don't think that the vaccine can be reliable as it is a new , COVID-19 infection is a biological weapon, and the vaccine will serve those who produce this virus [45] . Fear of the unknown is a driver of vaccine hesitancy. This study showed that 1st and 2nd dose post-vaccination adverse reactions of Sinopharm COVID-19 vaccine were common side effects, mild, predictable, non-life-threatening, and none were serious. To our knowledge, this is the first design dealing with the Sinopharm vaccine side and evaluating the side effects among a UAE population, the results may help reduce vaccine hesitancy of the public. The authors declare no conflict of interest. Resolution of coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges Coronavirus disease (COVID-19): How is it transmitted Investigational treatments for COVID-19 Vaccine: Critical Questions with Complicated Answers Correction to: Assessing the Safety of COVID-19 Vaccines: A Primer Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials COVID-19 Commission of Accademia Nazionale deiLincei, Rome. COVID-19 vaccines: Where we stand and challenges ahead A Review of the Progress and Challenges of Developing a Vaccine for COVID-19 China to run human coronavirus vaccine trial in UAE Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 Arab nations first to approve Chinese COVID vaccine -despite lack of public data A review on COVID-19 vaccines: stages of clinical trials, mode of actions and efficacy Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine, for recommendation by the strategic advisory group of experts (sage) on immunization prepared by the sage working group on covid-19 vaccines Survey of symptoms following COVID-19 vaccination in India Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects Global Prevalence and Drivers of Dental Students' COVID-19 Vaccine Hesitancy World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet COVID-19 Vaccine The Assessment of Reliability Interrater reliability: the kappa statistic Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Stud China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says Report on Evaluation of Safety, Efficacy and Quality of CoronaVac COVID-19 Vaccine (Vero Cell) Inactivated. 2021 Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey The how's and what's of vaccine reactogenicity. npj Vaccines Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine Possible Side Effects After Getting a COVID-19 Vaccine The Xs and Y of immune responses to viral vaccines Sex-based biology and the rational design of influenza vaccination strategies Ming-Yow Hung M. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations Delayed Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review Barriers affecting compliance of patients with chronic diseases: A preliminary study in United Arab Emirates (UAE) population About 20% of people in recent survey said they wouldn't take COVID-19 vaccine Coronavirus causing some anti-vaxxers to waver, experts say While studies on COVID-19 vaccine is ongoing, the public's thoughts and attitudes to the future COVID-19 vaccine No. Agree to take the vaccine 800 74%